Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
If you are considering launching a drug program in the burgeoning JAPAC market, it is important to familiarize your team with regulatory nuances and safety initiatives across the region. IQVIA's white paper outlines the safety strategies and regulatory considerations of drug development in the Japan and Asia-Pacific (JAPAC) region. It explores the rapidly growing biopharma market, the distinct regulatory nuances of each country, and the role of technology in pharmacovigilance. The piece also highlights the adoption of International Council for Harmonization (ICH) guidelines in China and Japan, offering crucial insights for businesses planning to launch drug programs in this region.
Download and learn how IQVIA can help you navigate the compliance intricacies of the JAPAC region.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
Harness the power of automation to execute streamlined end-to-end safety solutions while reducing costs.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
Reimagine regulatory service delivery.
Harness the power of global human expertise combined with automation, artificial intelligence (AI) and machine learning (ML) to design, build and execute end-to-end safety solutions.